Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Liraglutid, ATC A10BJ02 für die Zeit 01.06.2025 - 31.05.2027 (zzgl. Verlängerungsoption 1x12 Monate)

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

March 29, 2028
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient liraglutide, ATC A10BJ02, for the period 01.06.2025 - 31.05.2027 (plus extension option of 1 x 12 months)

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedApril 17, 2025
Procurement stageActive solicitation
Response dueMarch 29, 2028
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Eltrombopag, ATC B02BX05
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Apremilast (ATC-Code nach WHO: L04AA32)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tiaprid, ATC N05AL03
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Natalizumab, i.v. Darreichungsform, ATC L04AG03
Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-14
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-06 - Pegvisomant
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.